BACKGROUND: Artificial urinary sphincter (AUS) placement is the standard for treatment of severe male stress urinary incontinence (SUI). While there is evidence to suggest satisfactory device survival, there is a paucity of data addressing long-term quality of life outcomes. METHODS: We identified patients who underwent primary AUS placement from 1983 to 2016. We assessed rates of secondary surgery (overall, device infection/erosion, urethral atrophy, malfunction) and factors associated with these endpoints. Quality of life was evaluated by pad usage and Patient Global Impression of Improvement (PGI-I) at various time points from primary surgery. Follow-up was obtained in clinic or by phoned/mailed correspondence. RESULTS: During the study time frame, 1,154 patients were eligible and included in the analysis. Patients had a median age of 70 years (IQR, 65-75 years) and median follow up of 5.4 years (IQR, 1.6-10.5 years). Overall device survival was 72% at 5 years, 56% at 10 years, 41% at 15 years, and 33% at 20 years. On univariate analysis, variables associated with need for secondary surgery were prior cryotherapy (HR 2.7; 95% CI, 1.6-4.6; P<0.01) or radiation therapy (HR 1.4; 95% CI, 1.1-1.7; P=0.01). On multivariable analysis, only cryotherapy remained significantly associated with this endpoint (HR 2.4; 95% CI, 1.3-4.2; P<0.01). While 36% and 23% of patients 5-10 years out from surgery and >10 years out from surgery, respectively, reported using a security pad or less per day, 78% and 81% of those patients, respectively, reported their PGI-I as at least "much better". CONCLUSIONS: AUS placement has excellent long-term outcomes, and is associated with sustained improvement in patient quality of life. 2020 Translational Andrology and Urology. All rights reserved.
BACKGROUND: Artificial urinary sphincter (AUS) placement is the standard for treatment of severe male stress urinary incontinence (SUI). While there is evidence to suggest satisfactory device survival, there is a paucity of data addressing long-term quality of life outcomes. METHODS: We identified patients who underwent primary AUS placement from 1983 to 2016. We assessed rates of secondary surgery (overall, device infection/erosion, urethral atrophy, malfunction) and factors associated with these endpoints. Quality of life was evaluated by pad usage and Patient Global Impression of Improvement (PGI-I) at various time points from primary surgery. Follow-up was obtained in clinic or by phoned/mailed correspondence. RESULTS: During the study time frame, 1,154 patients were eligible and included in the analysis. Patients had a median age of 70 years (IQR, 65-75 years) and median follow up of 5.4 years (IQR, 1.6-10.5 years). Overall device survival was 72% at 5 years, 56% at 10 years, 41% at 15 years, and 33% at 20 years. On univariate analysis, variables associated with need for secondary surgery were prior cryotherapy (HR 2.7; 95% CI, 1.6-4.6; P<0.01) or radiation therapy (HR 1.4; 95% CI, 1.1-1.7; P=0.01). On multivariable analysis, only cryotherapy remained significantly associated with this endpoint (HR 2.4; 95% CI, 1.3-4.2; P<0.01). While 36% and 23% of patients 5-10 years out from surgery and >10 years out from surgery, respectively, reported using a security pad or less per day, 78% and 81% of those patients, respectively, reported their PGI-I as at least "much better". CONCLUSIONS: AUS placement has excellent long-term outcomes, and is associated with sustained improvement in patient quality of life. 2020 Translational Andrology and Urology. All rights reserved.
Authors: Simon P Kim; Zubair Sarmast; Stephanie Daignault; Gary J Faerber; Edward J McGuire; Jerilyn M Latini Journal: J Urol Date: 2008-03-18 Impact factor: 7.450
Authors: Frank Van der Aa; Marcus J Drake; George R Kasyan; Andreas Petrolekas; Jean-Nicolas Cornu Journal: Eur Urol Date: 2012-11-23 Impact factor: 20.096
Authors: Malcolm G Lucas; Ruud J L Bosch; Fiona C Burkhard; Francisco Cruz; Thomas B Madden; Arjun K Nambiar; Andreas Neisius; Dirk J M K de Ridder; Andrea Tubaro; William H Turner; Robert S Pickard Journal: Eur Urol Date: 2012-08-31 Impact factor: 20.096
Authors: Joceline S Liu; Matthias D Hofer; Jaclyn Milose; Daniel T Oberlin; Sarah C Flury; Allen F Morey; Chris M Gonzalez Journal: Urology Date: 2015-09-04 Impact factor: 2.649
Authors: Anne M Suskind; Rodney L Dunn; Daniel M Morgan; John O L DeLancey; Edward J McGuire; John T Wei Journal: Neurourol Urodyn Date: 2013-08-14 Impact factor: 2.696
Authors: Roger K Khouri; Nicolas M Ortiz; Benjamin M Dropkin; Gregory A Joice; Adam S Baumgarten; Allen F Morey; Steven J Hudak Journal: Curr Urol Rep Date: 2021-03-29 Impact factor: 3.092
Authors: Peter Rehder; Jannik Stuehmeier; Lukas Andrius Jelisejevas; Alexandra Gulacsi; Wolgang Horninger; Marco Pedrini Journal: Urol Case Rep Date: 2020-05-06